A detailed history of Valmark Advisers, Inc. transactions in Eli Lilly & CO stock. As of the latest transaction made, Valmark Advisers, Inc. holds 5,980 shares of LLY stock, worth $4.46 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
5,980
Previous 5,736 4.25%
Holding current value
$4.46 Million
Previous $5.19 Million 2.0%
% of portfolio
0.08%
Previous 0.09%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$772.14 - $960.02 $188,402 - $234,244
244 Added 4.25%
5,980 $5.3 Million
Q2 2024

Jul 31, 2024

BUY
$724.87 - $909.04 $105,831 - $132,719
146 Added 2.61%
5,736 $5.19 Million
Q1 2024

May 03, 2024

BUY
$592.2 - $792.28 $620,033 - $829,517
1,047 Added 23.05%
5,590 $4.35 Million
Q4 2023

Feb 02, 2024

BUY
$525.19 - $619.13 $36,238 - $42,719
69 Added 1.54%
4,543 $2.65 Million
Q3 2023

Nov 07, 2023

BUY
$434.7 - $599.3 $1,738 - $2,397
4 Added 0.09%
4,474 $2.4 Million
Q2 2023

Aug 02, 2023

SELL
$350.74 - $468.98 $55,066 - $73,629
-157 Reduced 3.39%
4,470 $2.1 Million
Q1 2023

May 01, 2023

SELL
$310.63 - $364.82 $4,970 - $5,837
-16 Reduced 0.34%
4,627 $1.59 Million
Q4 2022

Feb 06, 2023

SELL
$321.55 - $374.67 $248,558 - $289,619
-773 Reduced 14.27%
4,643 $1.7 Million
Q3 2022

Nov 02, 2022

BUY
$296.48 - $337.87 $45,954 - $52,369
155 Added 2.95%
5,416 $1.75 Million
Q2 2022

Aug 01, 2022

SELL
$278.73 - $327.27 $71,076 - $83,453
-255 Reduced 4.62%
5,261 $1.71 Million
Q1 2022

May 10, 2022

BUY
$234.69 - $291.66 $102,324 - $127,163
436 Added 8.58%
5,516 $1.58 Million
Q4 2021

Feb 02, 2022

BUY
$224.85 - $279.04 $328,955 - $408,235
1,463 Added 40.45%
5,080 $1.4 Million
Q3 2021

Nov 09, 2021

BUY
$221.6 - $272.71 $2,659 - $3,272
12 Added 0.33%
3,617 $836,000
Q2 2021

Aug 06, 2021

BUY
$180.55 - $233.54 $8,124 - $10,509
45 Added 1.26%
3,605 $827,000
Q1 2021

May 04, 2021

BUY
$164.32 - $212.72 $68,357 - $88,491
416 Added 13.23%
3,560 $665,000
Q4 2020

Feb 03, 2021

BUY
$130.46 - $172.63 $26,613 - $35,216
204 Added 6.94%
3,144 $531,000
Q3 2020

Nov 09, 2020

SELL
$146.22 - $169.13 $2,778 - $3,213
-19 Reduced 0.64%
2,940 $435,000
Q2 2020

Jul 31, 2020

BUY
$136.42 - $164.18 $54,431 - $65,507
399 Added 15.59%
2,959 $486,000
Q1 2020

May 01, 2020

BUY
$119.05 - $147.35 $49,286 - $61,002
414 Added 19.29%
2,560 $355,000
Q4 2019

Jan 31, 2020

BUY
$106.92 - $132.43 $5,559 - $6,886
52 Added 2.48%
2,146 $282,000
Q3 2019

Nov 06, 2019

BUY
$106.79 - $116.16 $15,057 - $16,378
141 Added 7.22%
2,094 $234,000
Q2 2019

Aug 07, 2019

SELL
$110.79 - $129.32 $24,595 - $28,709
-222 Reduced 10.21%
1,953 $216,000
Q1 2019

May 10, 2019

BUY
$111.31 - $131.02 $11,464 - $13,495
103 Added 4.97%
2,175 $282,000
Q4 2018

Feb 07, 2019

BUY
$105.9 - $118.64 $219,424 - $245,822
2,072 New
2,072 $240,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $709B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Valmark Advisers, Inc. Portfolio

Follow Valmark Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Valmark Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Valmark Advisers, Inc. with notifications on news.